Positron Emission Tomography
35
16
17
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 35 trials
100.0%
+13.4% vs benchmark
6%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (35)
PSMA PET Combined With MRI for the Detection of PCa
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
PET-CT Predicting Lymph Nodes Metastasis
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
Serotonin Release in Premotor and Motor PD
Longitudinal Investigation of I2BS in PD
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Pancreatic Cancer Diagnosis With FAPI-PET Imaging
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
FAPI PET/CT in Various FAP-Related Disease Patients
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging